H.R. 19 117th Congress
Lower Costs, More Cures Act of 2021
- Health
- Sponsor: Rep. McMorris Rodgers, Cathy [R-WA-5]
- Congress.gov ↗
Latest action, Oct 19, 2021: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
133 cosponsors
Sponsored by Rep. McMorris Rodgers, Cathy [R-WA-5] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
0 D · 133 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee; House: Judiciary Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMAC ACTION, INC.
SCHOENING STRATEGIES, LLC
8 reports
8 reports
8 reports
8 reports
8 reports
7 reports
7 reports
7 reports
7 reports
BIOMARIN PHARMACEUTICAL INC.
CHAMBER HILL STRATEGIES
7 reports
BOEHRINGER INGELHEIM USA CORPORATION
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
7 reports
7 reports
7 reports
All 25 of 99 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMAC ACTION, INC. | SCHOENING STRATEGIES, LLC | 8 | $0 | Q1 2021 | Q3 2022 | yes |
| BIOGEN | 8 | $7.9M | Q1 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 8 | $9.8M | Q1 2021 | Q3 2022 | yes | |
| MERCK & CO INC | 8 | $16.3M | Q1 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 8 | $57.9M | Q1 2021 | Q3 2022 | yes | |
| SCAN HEALTH PLAN | 8 | $1.5M | Q1 2021 | Q3 2022 | yes | |
| AMERICAN MEDICAL ASSOCIATION | 7 | $33.0M | Q4 2021 | Q3 2022 | yes | |
| ARTHRITIS FOUNDATION | 7 | $525K | Q4 2021 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 7 | $8.2M | Q4 2021 | Q3 2022 | yes | |
| BAXTER HEALTHCARE CORPORATION | 7 | $3.4M | Q4 2021 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | CHAMBER HILL STRATEGIES | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $23.5M | Q4 2021 | Q3 2022 | yes | |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 7 | $7.0M | Q4 2021 | Q3 2022 | yes |
| CAMBIA HEALTH SOLUTIONS | 7 | $3.3M | Q4 2021 | Q3 2022 | yes | |
| HUMANA INC | 7 | $8.4M | Q1 2021 | Q3 2022 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 7 | $8.9M | Q4 2021 | Q3 2022 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $6.1M | Q4 2021 | Q3 2022 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 7 | $357K | Q4 2021 | Q3 2022 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $14.1M | Q4 2021 | Q3 2022 | yes | |
| PRIME THERAPEUTICS | 7 | $580K | Q1 2021 | Q3 2022 | yes | |
| REGENXBIO | 7 | $537K | Q1 2021 | Q3 2022 | yes | |
| TEVA PHARMACEUTICALS USA INC | 7 | $6.0M | Q4 2021 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | 7 | $1.1M | Q4 2021 | Q3 2022 | yes | |
| ABBVIE INC. | 6 | $11.1M | Q4 2021 | Q3 2022 | yes | |
| ALKERMES, INC. | 6 | $4.3M | Q4 2021 | Q3 2022 | yes |